Organization (Industry)
Jiangsu Kanion Pharmaceutical Co., Ltd
ClinicalTrials.gov lists Jiangsu Kanion Pharmaceutical Co., Ltd as lead sponsor of 13 trials. It has 6 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Jiangsu Kanion Pharmaceutical Co., Ltd: 13 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Ischemic Stroke | 4 |
| Stroke | 4 |
| Chikungunya Fever | 1 |
| Dysmenorrhea | 1 |
| Endometriosis | 1 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2014 | 4 |
| 2013 | 2 |
| 2012 | 1 |
| 2010 | 1 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Single dose, AAPB by injection, intravenous drip. | Ischemic Stroke | Phase 1 | 1 |
| Single dose, AAPB by injection, intravenous drip. | Stroke | Phase 1 | 1 |
| Multiple dosing, AAPB for injection, intravenous drip | Ischemic Stroke | Phase 1 | 1 |
| Multiple dosing, AAPB for injection, intravenous drip | Stroke | Phase 1 | 1 |
| The simulant of Reduning Injection | Chikungunya Fever | Not reported | 1 |
Showing 5 of 6 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ginkgolides Meglumine Injection | 3 |
| Tianshu capsule | 1 |
| Sanjie analgesic capsule | 1 |
| 0.1mg/ml Ginkgolides Meglumine Injection | 1 |
| 1mg/ml Ginkgolides Meglumine Injection | 1 |
Showing 5 of 7 approved assets.
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMC complementary and alternative medicine | 1 |
| Chinese journal of integrative medicine | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18 | 9 | 2025-12-16 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2021-04-12 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Beijing Bionovo Medicine Development Co., Ltd. | Co sponsors trial with | 1 |
Latest dated events (37)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-09-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-11-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 37 events.
Biomarker capability evidence (14)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP2C9 | Trial sponsor | Named in trial exclusion criteria |
| CYP2D6 | Trial sponsor | Named in trial exclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
| CYP3A5 | Trial sponsor | Named in trial exclusion criteria |
| PAPOLA | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 14 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.